Shigeki Seki
About
In The Last Decade
Shigeki Seki
10 papers receiving 674 citations
Peers
Comparison fields: 5 of 59
- Pulmonary and Respiratory Medicine 512
- Surgery 446
- Oncology 186
- Molecular Biology 83
- Gastroenterology 56
Countries citing papers authored by Shigeki Seki
This map shows the geographic impact of Shigeki Seki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeki Seki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeki Seki more than expected).
Fields of papers citing papers by Shigeki Seki
This network shows the impact of papers produced by Shigeki Seki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeki Seki. The network helps show where Shigeki Seki may publish in the future.
Co-authorship network of co-authors of Shigeki Seki
This figure shows the co-authorship network connecting the top 25 collaborators of Shigeki Seki. A scholar is included among the top collaborators of Shigeki Seki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigeki Seki. Shigeki Seki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 4 | |
| 3 | 229 | |
| 4 | 362 | |
| 5 | 54 | |
| 6 | 2 | |
| 7 | 5 | |
| 8 | Prognosis of non-Hodgkin's lymphoma 1. T- and B-lymphoma and its primary site.:1. T- and B-lymphoma and its primary site | 4 |
| 9 | [Prognosis of non-Hodgkin's lymphoma. 2. T- and B-lymphoma and clinical stage]. | 1 |
| 10 | A novel human myelomonocytoid cell line, P39/Tsugane, derived from overt leukemia following myelodysplastic syndrome. | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.